Timing is everything for compassionate use of delamanid.
作者信息
Barry Clifton E
机构信息
Tuberculosis Research Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Nat Med. 2015 Mar;21(3):211. doi: 10.1038/nm.3823.
Abstract
摘要
相似文献
1
Timing is everything for compassionate use of delamanid.对于德拉马尼的同情用药而言，时机至关重要。
Nat Med. 2015 Mar;21(3):211. doi: 10.1038/nm.3823.
2
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.实地记录：2017年美国在广泛耐药结核病同情用药项目下获取地拉曼尼的情况
MMWR Morb Mortal Wkly Rep. 2018 Sep 7;67(35):996-997. doi: 10.15585/mmwr.mm6735a6.
3
Access sought to tuberculosis drug from nutraceutical company.寻求从营养保健品公司获取抗结核药物。
Nat Med. 2015 Feb;21(2):103. doi: 10.1038/nm.3805. Epub 2015 Feb 2.
4
Delamanid for Extensively Drug-Resistant Tuberculosis.地拉米司用于广泛耐药结核病
N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332.
5
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.首例广泛耐药结核病使用德拉马尼和贝达喹啉治疗。
Eur Respir J. 2016 Sep;48(3):935-8. doi: 10.1183/13993003.00637-2016. Epub 2016 Jun 10.
6
Bedaquiline plus delamanid for XDR tuberculosis.贝达喹啉联合地拉马尼治疗广泛耐药结核病
Lancet Infect Dis. 2016 Mar;16(3):294. doi: 10.1016/S1473-3099(16)00047-5.
7
Compassionate and optimum use of new tuberculosis drugs.新型结核病药物的合理与优化使用。
Lancet Infect Dis. 2015 Oct;15(10):1131-1132. doi: 10.1016/S1473-3099(15)00296-0. Epub 2015 Sep 20.
8
Compassionate and optimum use of new tuberculosis drugs.新型结核病药物的合理与优化使用。
Lancet Infect Dis. 2015 Oct;15(10):1131. doi: 10.1016/S1473-3099(15)00294-7. Epub 2015 Sep 20.
9
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.在耐多药结核病治疗期间低水平地奈达胺和贝达喹啉耐药的出现。
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.
10
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.拉脱维亚接受含地拉曼尼方案治疗的耐多药和广泛耐药结核病患者的最终治疗结果
Eur Respir J. 2017 Nov 9;50(5). doi: 10.1183/13993003.01105-2017. Print 2017 Nov.
引用本文的文献
1
Anti-Tubercular Properties of 4-Amino-5-(4-Fluoro-3- Phenoxyphenyl)-4-1,2,4-Triazole-3-Thiol and Its Schiff Bases: Computational Input and Molecular Dynamics.4-氨基-5-(4-氟-3-苯氧基苯基)-4H-1,2,4-三唑-3-硫醇及其席夫碱的抗结核特性：计算输入与分子动力学
Antibiotics (Basel). 2020 Aug 31;9(9):559. doi: 10.3390/antibiotics9090559.
2
In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against .计算机辅助设计和合成四氢嘧啶酮和四氢嘧啶硫酮作为潜在的胸苷酸激酶抑制剂，对.发挥抗结核活性。
Drug Des Devel Ther. 2020 Mar 9;14:1027-1039. doi: 10.2147/DDDT.S228381. eCollection 2020.
3
Anti-Tubercular Activity of Substituted 7-Methyl and 7-Formylindolizines and In Silico Study for Prospective Molecular Target Identification.取代的7-甲基和7-甲酰基中氮茚的抗结核活性及用于潜在分子靶点鉴定的计算机模拟研究
Antibiotics (Basel). 2019 Dec 3;8(4):247. doi: 10.3390/antibiotics8040247.
4
Computational, crystallographic studies, cytotoxicity and anti-tubercular activity of substituted 7-methoxy-indolizine analogues.计算化学、晶体学研究、取代 7-甲氧基吲哚嗪类似物的细胞毒性和抗结核活性。
PLoS One. 2019 Jun 4;14(6):e0217270. doi: 10.1371/journal.pone.0217270. eCollection 2019.
5
Current strategies to treat tuberculosis.治疗结核病的当前策略。
F1000Res. 2016 Oct 26;5. doi: 10.12688/f1000research.7403.1. eCollection 2016.
6
Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.苯并噻唑硫酮是一种治疗耐药性结核病的有潜力的临床前候选药物。
Sci Rep. 2016 Jul 13;6:29717. doi: 10.1038/srep29717.
7
Next-generation antimicrobials: from chemical biology to first-in-class drugs.下一代抗菌药物：从化学生物学到一流药物
Arch Pharm Res. 2015 Sep;38(9):1702-17. doi: 10.1007/s12272-015-0645-0. Epub 2015 Aug 11.
本文引用的文献
1
Access sought to tuberculosis drug from nutraceutical company.寻求从营养保健品公司获取抗结核药物。
Nat Med. 2015 Feb;21(2):103. doi: 10.1038/nm.3805. Epub 2015 Feb 2.
2
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.巴喹替尼治疗耐多药和广泛耐药结核病的同情使用：法国队列的中期分析。
Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15.
3
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.欧洲呼吸学会/世界卫生组织结核病咨询委员会对一名儿童广泛耐药结核病管理的援助：使用德拉马尼的同情用药案例研究
Eur Respir J. 2014 Sep;44(3):811-5. doi: 10.1183/09031936.00060414. Epub 2014 May 15.
4
Delamanid for multidrug-resistant pulmonary tuberculosis.德拉马尼治疗耐多药肺结核。
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
5
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.新型 TMC207 和 PA-824 联合方案在结核分枝杆菌感染小鼠模型中的杀菌活性。
Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11. Epub 2011 Sep 19.
Zotero 插件